Fig. 1-1.
Fig. 1-1. Representative isoboles for the Philadelphia chromosome–positive K562 and MEG-1 tumor cells treated with various concentrations of SCH66336/lonafarnib and STI571/imatinib. / Ten concentrations of FTI SCH66336 ranging from 20 μM to 0.03 μM and 6 concentrations of STI571 ranging from 2 μM to 0.05 μM were tested. Cell proliferation was quantified on days 2, 3, and 4 after compound addition by methyl-thiazol tetrazolium (MTT) assay. Cell proliferation data from drug interaction studies were analyzed using the Thin Plate Spline methodology (G. Hajian, L. Hothorn, manuscript submitted; O'Connell and Wolfinger1-2) as described previously.1-3 Data (day 3) reflect a left-shifted isobologram for both cell lines, consistent with a synergistic combination effect on cell viability.

Representative isoboles for the Philadelphia chromosome–positive K562 and MEG-1 tumor cells treated with various concentrations of SCH66336/lonafarnib and STI571/imatinib.

Ten concentrations of FTI SCH66336 ranging from 20 μM to 0.03 μM and 6 concentrations of STI571 ranging from 2 μM to 0.05 μM were tested. Cell proliferation was quantified on days 2, 3, and 4 after compound addition by methyl-thiazol tetrazolium (MTT) assay. Cell proliferation data from drug interaction studies were analyzed using the Thin Plate Spline methodology (G. Hajian, L. Hothorn, manuscript submitted; O'Connell and Wolfinger1-2) as described previously.1-3 Data (day 3) reflect a left-shifted isobologram for both cell lines, consistent with a synergistic combination effect on cell viability.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal